TB-500 (Thymosin-β4 fragment) is often discussed in the biohacking community as a “regeneration shortcut.” What matters, however, is this: Which effects have been shown in humans in RCTs—and which have not? At the same time, it’s important to separate evidence for Thymosin β4 (the active ingredient) from evidence for the specific TB-500 product (commercial, fragment identified/analytically characterized). Below you’ll find a sober breakdown of what is supported, where the boundaries are, and what information is missing for safety/efficacy.
Before talking about TB-500: The levers with the best evidence
TB-500 is not a lifestyle lever. If your goal is “regeneration” or “healing,” then sleep, load-oriented training, and inflammation reduction are typically the knobs with the best evidence—because they target measurable, repeatedly adjustable endpoints (pain, function, recovery). Only once a medically relevant problem is clearly defined (e.g., an ulcer, a severe dry eye condition) does it make sense to consider pharmacological/biological interventions.
Why this matters for TB-500: Even if Thymosin β4 shows effects in certain indications in an RCT context (see below), that does not mean TB-500 has the same hit rate for “performance,” general regeneration, or anti-aging. For such broad, generic goals, there are currently no suitable human RCTs. In practice, this is the most common reason people report “results” that cannot be cleanly attributed scientifically.
If you’re still considering TB-500, start by defining a clear target: What exactly should improve—symptoms (e.g., complaints), a clinical finding (e.g., healing rate), or a functional endpoint? This doesn’t just fit better with study designs; it also determines what adverse effects you might realistically expect.
And crucially: If you have a medically relevant condition, you do not replace medical care with “research chemicals.” This is especially true for venous ulcers or relevant eye diseases. The evidence base for Thymosin β4 is limited to specific contexts; you cannot generalize that into a blanket rationale for self-medication (see also Bias: Effects & Evidence Base – what’s supported and what’s missing).
What TB-500 actually is—and why it matters for the evidence
In practice, TB-500 is marketed in connection with Thymosin β4 or an N-terminal acetylated fragment (17–23). The relevant study from the list supports the chemical/analytical identification: Simone et al. (2012, PMID 22962027) describes the synthesis and characterization of the N-terminal acetylated 17–23 fragment that was identified as part of TB-500 and is suspected to be doping-relevant. This is important—but it is not the same as clinical efficacy.
The central evidence limitation: Many human RCTs you find in the literature test Thymosin β4 as the active ingredient in a defined pharmaceutical/study context. That means: even if Thymosin β4 shows certain effects in RCTs (e.g., for dry eye or venous ulcers), transferability to “TB-500” as a specific commercial product is not automatically guaranteed. The reason is straightforward but decisive: composition, exact form (fragment vs full protein/other fragments), manufacturing quality, purity, route of administration, and pharmacokinetics can differ—and these factors determine what actually reaches the body.
For a clean evaluation, you should therefore separate the evidence:
- Evidence for Thymosin β4 in studies (what was actually measured in RCTs),
- Evidence that TB-500 analytically contains the marketed fragment (Simone et al., 2012, PMID 22962027),
- and ideally direct clinical data on TB-500 as a product (which, in your list, are not available in the form of RCTs specifically for TB-500).
In short: The list contains strong signals that Thymosin β4 has been studied in humans in certain indications—but for TB-500 as a product, clinical evidence is limited, and for many goals it is simply not present. This is not a matter of opinion; it follows directly from study design and how evidence is distinguished.
Evidence hierarchy: which data on RCTs, pharmacokinetics, and fragments applies
For the question “does it work in humans?”, the highest-quality evidence is usually randomized controlled trials. In this study list, those designs are present—covering multiple indications as well as pharmacokinetics/safety aspects in healthy participants. For a complete picture, you should check whether the work is placebo-controlled, how the endpoints are defined, and whether there are phase 1/2 data on tolerability.
In your list, you’ll find:
- RCTs on efficacy/clinical symptoms: e.g., dry eye (Sosne et al., 2015, PMID 25826322) and venous ulcers (Guarnera et al., 2010, PMID 20536470; Guarnera et al., 2007, PMID 17495250).
- RCTs/pilot-RCTs with cardiovascular endpoints in the context of Tβ4: e.g., Choudry et al. (2015, PMID 26022762) as an RCT setting for plasma Tβ4 after intracardiac cell therapy with symptomatic improvement; and Zhu et al. (2016, PMID 27288307) as a pilot study of autologous Tβ4-pretreated endothelial cell transplantation in acute STEMI.
- Pharmacokinetics and safety in healthy participants: Ruff et al. (2010, PMID 20536472) investigates single- and multiple-dose intravenous Thymosin β4 in a placebo-controlled design. In addition, there is a phase-1 study: Wang et al. (2021, PMID 34346165) as a first-in-human randomized/double-blind study in healthy participants (with single- and multiple-dose recombinant human Thymosin β4).
- Analytics/fragment assignment: Simone et al. (2012, PMID 22962027) is an identification/characterization paper—relevant for “what is TB-500 chemically?”, but not as evidence of clinical efficacy.
A common discussion error: you see a positive RCT for “Thymosin β4” and infer that “TB-500 works like the product.” That is not methodologically clean. Even within the same biological family, the form of the active ingredient, the route of administration, and exposure can vary. That’s why the evidence hierarchy is doubly important here: which study actually answers your specific question?
If you also want to understand why effect sizes and endpoints often “wobble,” it can help to read Understanding effect sizes: effects & evidence base of 1–2 levers—that’s exactly the point most often lost in supplement/biohacking discussions.
What the 7 (or 8) studies report specifically: symptoms, healing, and safety data
In the present study list, there are several RCT/phase-1 data points on clinical symptoms and safety profiles. At the same time, the list isn’t universal; it’s indication-specific. Many results relate to dry eye, venous ulcers, and cardiovascular contexts, while generic goals like performance/aging are not cleanly supported by RCTs.
-
Dry eye Sosne et al. (2015, PMID 25826322) report in a phase-2 RCT that Thymosin β4 improves signs and symptoms of severe dry eye. This is one of the most directly relevant clinical efficacy categories in the list. Important caveat: the effect applies to the symptoms/signs measured in the study—not to “general regeneration.”
-
Venous ulcers Guarnera et al. (2010, PMID 20536470) study Thymosin in venous ulcers in an RCT design and report effects on wound status. Complementing this, Guarnera et al. (2007, PMID 17495250) focus on clinical remarks in a European prospective randomized setting (including safety/tolerability as well as improved healing). For the theme “wound healing,” these two studies are the most important in this list.
-
Cardiovascular contexts (Tβ4 as concomitant/pre-treatment variable) Choudry et al. (2015, PMID 26022762) consider an RCT context in which increases in Tβ4 in plasma after intracardiac cell therapy are associated with symptomatic improvement. Zhu et al. (2016, PMID 27288307) report in a pilot study of autologous Tβ4-pretreated endothelial cell transplantation in acute STEMI on safety and efficacy in this specific setting. These studies are not “TB-500 for performance”; they are concrete medical applications.
-
Safety and pharmacokinetics in healthy participants Ruff et al. (2010, PMID 20536472) provide placebo-controlled data on intravenous Thymosin β4 in single- and multiple-dose designs in healthy participants. This is relevant to the question: “What does it do in the body and how is it tolerated?” Wang et al. (2021, PMID 34346165) reports as a first-in-human phase-I randomized/double-blind study on recombinant human Thymosin β4 in healthy participants, again covering single- and multiple-dose exposure.
-
TB-500 fragment identification Simone et al. (2012, PMID 22962027) provides the synthesis and characterization of the N-terminal acetylated 17–23 fragment, which TB-500 is meant to contain and which is suspected to be doping-relevant. This is an analytical component, but not a clinical efficacy study.
What’s important for “what you can infer”: The list contains no robust direct RCTs on TB-500 as a product for performance/anti-aging. Therefore, this expectation pathway remains scientifically unsupported.
Study comparison: indication, design, evidence weight, and what that implies for TB-500
The following studies differ substantially in indication and design. The clear consequence is: evidence exists for specific medical goals (e.g., dry eye, venous ulcers), while extrapolating to TB-500 as a general regeneration or anti-aging product is not methodologically clean. For TB-500, there’s an additional question: whether it is truly identical in exposure, formulation, and dosing compared with the Thymosin β4 used in the RCTs.
| Study (PMID) | Indication/setting | Study design & evidence weight | What was shown/covered |
|---|---|---|---|
| Sosne et al. (PMID 25826322) | Severe dry eye | Phase-2 RCT; high for clinical symptoms | Thymosin β4 improves signs/symptoms in dry eye |
| Guarnera et al. (PMID 20536470) | Venous ulcers | RCT; high for wound/healing endpoints | Effects on the wound situation |
| Guarnera et al. (PMID 17495250) | Venous ulcers | Prospective randomized; medium/high (depending on endpoint details in the protocol) | Clinical remarks on safety/tolerability and healing |
| Ruff et al. (PMID 20536472) | Healthy participants | Placebo-controlled RCT; high for safety/PK context | Single- and multiple-dose intravenous: tolerability/PK framework |
| Wang et al. (PMID 34346165) | Healthy participants | First-in-human phase I, randomized/double-blind | Safety/PK framework for recombinant human Thymosin β4 |
| Choudry et al. (PMID 26022762) | Chronic ischemic heart failure (cell therapy context) | RCT setting; indirect mechanism | Plasma Tβ4 increase associated with symptomatic improvement |
| Zhu et al. (PMID 27288307) | Acute STEMI (cell transplantation context) | Pilot study; low/mid for generalization | Safety and (indication-specific) efficacy in this specific setup |
| Simone et al. (PMID 22962027) | Chemical assignment of TB-500 | Identification/characterization study; not for efficacy | N-term acetylated 17–23 fragment in relation to TB-500 |
What follows for TB-500:
- If your goal is “wound healing” for venous ulcers or “improving dry eye symptoms,” the direct study direction exists in this list—but it applies to Thymosin β4 in the study context, not automatically to TB-500 as a product.
- For “performance” or “anti-aging,” this list does not include a reliable RCT evidence profile. Accordingly, transfer to those goals is not serious.
- Safety interpretation: Data from Ruff (PMID 20536472) and Wang (PMID 34346165) are relevant because they examine intravenous/recombinant Thymosin β4 in healthy participants in a phase-1/PK context. Still, it remains: these are study protocols; that does not translate into a general, application- or product-wide clearance.
If you want to critically frame doping/regulatory realities, it can be helpful to read “Doping reality” further down—there it explains what Simone (PMID 22962027) actually supports and what it does not.
Safety, doping reality, and legal/clinical risks—without hype
With TB-500, the category “doping” is often discussed. Simone et al. (2012, PMID 22962027) in your list mainly supports the synthesis and characterization of the N-terminal acetylated 17–23 fragment associated with TB-500 and suspected to be doping-relevant. This is an important analytical signal—but it is not a blank check for safety in practice, and certainly not a replacement for clinical tolerability data.
The truly decisive safety information in this list comes from the human studies in healthy participants:
- Ruff et al. (2010, PMID 20536472) with placebo-controlled single- and multiple-dose intravenous Thymosin β4 (safety and pharmacokinetics context).
- Wang et al. (2021, PMID 34346165) as a first-in-human phase-I randomized/double-blind study with single- and multiple-dose recombinant human Thymosin β4 (again, safety/PK context).
Still: You cannot derive a blanket contraindication list for “TB-500 itself” from these studies without knowing the specific protocols (e.g., exact dosing regimens, inclusion criteria, monitoring, and adverse event definitions). That is the boundary of this evidence. That is why this article also won’t provide “general dosage and safety tips” pretending to be reliably transferable—the data are present in the list, but a full mapping of protocol details was not provided to you.
In addition to safety, there is the clinical risk: If you use TB-500 to address a medical problem that is not represented in the study settings, you are making decisions outside the evidence base. Especially for venous ulcers (Guarnera et al., 2010, PMID 20536470; Guarnera et al., 2007, PMID 17495250) or severe eye problems (Sosne et al., 2015, PMID 25826322), medical evaluation is essential—because treatment success depends not only on a biological intervention, but also on diagnosis, infection control, compression, baseline therapy, and more.
In short: If you consider an application despite uncertainty, at least do so as a medically supervised case with clean indication checking. Even then, it remains a tradeoff: the evidence in this list is mostly indication- and protocol-bound, not intended as a general self-experiment for anti-aging or performance.
Key takeaways
- Thymosin β4 has been studied in humans in RCTs for specific indications (e.g., dry eye: Sosne et al., 2015, PMID 25826322; venous ulcers: Guarnera et al., 2010, PMID 20536470; Guarnera et al., 2007, PMID 17495250). TB-500 as a product is not automatically covered 1:1 by this.
- The list provides safety/pharmacokinetics context from studies in healthy participants (Ruff et al., 2010, PMID 20536472; Wang et al., 2021, PMID 34346165), but without complete protocol details, no reliable “general dosing/contraindication guidance” can be derived.
- For “performance” or “anti-aging,” the evidence base from the cited human studies is currently not robust; there are no matching RCTs in exactly those target areas.
- Fragment identification (Simone et al., 2012, PMID 22962027) is analytically relevant, but it does not answer the efficacy and safety question for your specific application.